Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ridaura

(Auranofin)

Phase 2Small molecule

LLegacy Health System

This medication is used to treat rheumatoid arthritis by reducing symptoms like joint pain, swelling, and morning stiffness. It works best when combined with rest and other non-drug treatments, though it typically takes 3-6 months to feel its full effect.[1] Ridaura is currently being investigated across 6 indications[3], with its most advanced program in Phase 2.[1]

Ridaura is one of 225 small molecule programs targeting HIV infection. It is currently in Phase 2.

6

Indications

13

Total Trials

1

Active Trials

224

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

HIV InfectionActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Ovarian CancerActive, not recruiting

GlioblastomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

HIV InfectionPhase 1/Phase 2

Active, not recruiting

Fallopian Tube CancerPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 2

Active, not recruiting

GlioblastomaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Ridaura

LLegacy Health System

PORTRAZZA

Lenvima

Imjudo

Immunotherapy

Bristol-Myers Squibb

Remeron

OOrganon and Co

Tyrosine Kinase Inhibitor

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Remission

NCT06805656

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Completed·MMayo Clinic·Phase 1/2·NCT01737502·29 enrolled

Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer

Withdrawn·MMayo Clinic·Phase 1·NCT02126527

Remission1 trial

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not yet recruiting·FFederal University of São Paulo·Phase 2·NCT06805656·70 enrolled

Fallopian Tube Cancer1 trial

Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·MMayo Clinic·Phase 1·NCT01747798·10 enrolled

Oral1 trial

Auranofin PK Following Oral Dose Administration

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02089048·15 enrolled

Glioblastoma1 trial

A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma

Completed·UUniversity of Ulm·Phase 1/2·NCT02770378·10 enrolled

7 more indications

HIV infection1 trial

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

Withdrawn·VVaccine and Gene Therapy Institute, Florida·Phase 1/2·NCT02176135

Chronic Lymphocytic Leukemia1 trial

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT01419691·15 enrolled

TED1 trial

TB Host Directed Therapy

Unknown status·TThe Aurum Institute NPC·Phase 2·NCT02968927·200 enrolled

Ovarian Cancer1 trial

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Terminated·MMayo Clinic·Phase 2·NCT03456700·22 enrolled

Paclitaxel1 trial

Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome

Completed·MMayo Clinic·Phase 2·NCT02063698·30 enrolled

HIV-11 trial

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

Completed·FFederal University of São Paulo·N/A·NCT02961829·30 enrolled

Unspecified1 trial

Auranofin for Giardia Protozoa

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02736968·93 enrolled

Regulatory

FDA Approval Timeline[4]

May 24, 1985

RIDAURA

NDA NDA018689

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Auranofin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Auranofin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Auranofin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018689). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Legacy Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLegacy Health System

Related News